Published in J Natl Cancer Inst on May 23, 2011
Screening for Prostate Cancer in Older Patients (PLCO Screening Trial) | NCT00002540
Screening for lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest (2013) 4.83
Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med (2013) 4.64
Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med (2013) 4.09
Selection criteria for lung-cancer screening. N Engl J Med (2013) 3.69
Predictive accuracy of the Liverpool Lung Project risk model for stratifying patients for computed tomography screening for lung cancer: a case-control and cohort validation study. Ann Intern Med (2012) 3.45
Mechanistic links between COPD and lung cancer. Nat Rev Cancer (2013) 2.28
Lung carcinogenesis by tobacco smoke. Int J Cancer (2012) 2.06
Time to smoke first morning cigarette and lung cancer in a case-control study. J Natl Cancer Inst (2014) 1.66
Circulating inflammation markers and prospective risk for lung cancer. J Natl Cancer Inst (2013) 1.59
Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. J Clin Oncol (2013) 1.54
The state of molecular biomarkers for the early detection of lung cancer. Cancer Prev Res (Phila) (2012) 1.49
Previous lung diseases and lung cancer risk: a pooled analysis from the International Lung Cancer Consortium. Am J Epidemiol (2012) 1.27
The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer (2012) 1.08
Screening for lung cancer with low-dose computed tomography: a review of current status. J Thorac Dis (2013) 1.01
Bridging the clinical gaps: genetic, epigenetic and transcriptomic biomarkers for the early detection of lung cancer in the post-National Lung Screening Trial era. BMC Med (2013) 0.96
A risk model for lung cancer incidence. Cancer Prev Res (Phila) (2012) 0.95
Lung cancer screening: review and performance comparison under different risk scenarios. Lung (2013) 0.94
Comparing benefits from many possible computed tomography lung cancer screening programs: extrapolating from the National Lung Screening Trial using comparative modeling. PLoS One (2014) 0.90
Bridging the etiologic and prognostic outlooks in individualized assessment of absolute risk of an illness: application in lung cancer. Eur J Epidemiol (2016) 0.90
Prediction of lung cancer risk in a Chinese population using a multifactorial genetic model. BMC Med Genet (2012) 0.89
Individualized risk prediction model for lung cancer in Korean men. PLoS One (2013) 0.88
Chemoprevention of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest (2013) 0.88
Pro-surfactant protein B as a biomarker for lung cancer prediction. J Clin Oncol (2013) 0.88
Lung cancer screening beyond low-dose computed tomography: the role of novel biomarkers. Lung (2014) 0.87
Lung cancer screening: history, current perspectives, and future directions. Arch Med Sci (2015) 0.86
Lung cancer screening: identifying the high risk cohort. J Thorac Dis (2015) 0.86
Fifty years of tobacco carcinogenesis research: from mechanisms to early detection and prevention of lung cancer. Cancer Prev Res (Phila) (2014) 0.86
Clinical applications of gene-based risk prediction for lung cancer and the central role of chronic obstructive pulmonary disease. Front Genet (2012) 0.85
Signal stratification of autoantibody levels in serum samples and its application to the early detection of lung cancer. J Thorac Dis (2013) 0.85
The cytokinesis-blocked micronucleus assay as a strong predictor of lung cancer: extension of a lung cancer risk prediction model. Cancer Epidemiol Biomarkers Prev (2014) 0.83
Demonstration program of population-based lung cancer screening in China: Rationale and study design. Thorac Cancer (2014) 0.83
What to do when a smoker's CT scan is "normal"?: Implications for lung cancer screening. Chest (2012) 0.83
Predictive Accuracy of the PanCan Lung Cancer Risk Prediction Model -External Validation based on CT from the Danish Lung Cancer Screening Trial. Eur Radiol (2015) 0.83
Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada. J Thorac Oncol (2014) 0.81
Should Never-Smokers at Increased Risk for Lung Cancer Be Screened? J Thorac Oncol (2015) 0.81
Screening for lung cancer using low-dose computed tomography: concerns about the application in low-risk individuals. Transl Lung Cancer Res (2015) 0.80
Chronic obstructive pulmonary disease and subsequent overall and lung cancer mortality in low-income adults. PLoS One (2015) 0.79
Visual assessment of early emphysema and interstitial abnormalities on CT is useful in lung cancer risk analysis. Eur Radiol (2015) 0.79
Biomarkers of risk to develop lung cancer in the new screening era. Ann Transl Med (2016) 0.78
Lung Cancer Risk Prediction Using Common SNPs Located in GWAS-Identified Susceptibility Regions. J Thorac Oncol (2015) 0.78
Lung cancer risk test trial: study design, participant baseline characteristics, bronchoscopy safety, and establishment of a biospecimen repository. BMC Pulm Med (2016) 0.77
Lung cancer screening: past, present and future. Clin Chest Med (2013) 0.76
Focused Analysis of Exome Sequencing Data for Rare Germline Mutations in Familial and Sporadic Lung Cancer. J Thorac Oncol (2016) 0.76
Prediction of lung cancer incidence on the low-dose computed tomography arm of the National Lung Screening Trial: A dynamic Bayesian network. Artif Intell Med (2016) 0.75
A review of cancer risk prediction models with genetic variants. Cancer Inform (2014) 0.75
Incorporating epistasis interaction of genetic susceptibility single nucleotide polymorphisms in a lung cancer risk prediction model. Int J Oncol (2016) 0.75
Combining Telomerase Reverse Transcriptase Genetic Variant rs2736100 with Epidemiologic Factors in the Prediction of Lung Cancer Susceptibility. J Cancer (2016) 0.75
Oral Cell DNA Adducts as Potential Biomarkers for Lung Cancer Susceptibility in Cigarette Smokers. Chem Res Toxicol (2016) 0.75
Personalized Risk Assessment in Never, Light, and Heavy Smokers in a prospective cohort in Taiwan. Sci Rep (2016) 0.75
Low-dose CT screening using hybrid iterative reconstruction: confidence ratings of diagnoses of simulated lesions other than lung cancer. Br J Radiol (2015) 0.75
Receiver operating characteristic analysis of prediction for gastric cancer development using serum pepsinogen and Helicobacter pylori antibody tests. BMC Cancer (2017) 0.75
Mouse double minute-2 homolog (MDM2)-rs2279744 polymorphism associated with lung cancer risk in a Northeastern Chinese population. Thorac Cancer (2015) 0.75
Risk factors assessment and risk prediction models in lung cancer screening candidates. Ann Transl Med (2016) 0.75
A lung cancer risk classifier comprising genome maintenance genes measured in normal bronchial epithelial cells. BMC Cancer (2017) 0.75
A simple model for predicting lung cancer occurrence in a lung cancer screening program: The Pittsburgh Predictor. Lung Cancer (2015) 0.75
Lung cancer screening with low-dose computed tomography. Radiol Clin North Am (2014) 0.75
Should Nonsmokers Be Excluded from Early Lung Cancer Screening with Low-Dose Spiral Computed Tomography? Community-Based Practice in Shanghai. Transl Oncol (2017) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature (2008) 18.21
Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet (2008) 16.17
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature (2008) 16.10
Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol (2004) 12.03
Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials (2000) 10.99
Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst (1994) 7.91
Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med (2006) 7.82
Cigarette smoking and bronchial carcinoma: dose and time relationships among regular smokers and lifelong non-smokers. J Epidemiol Community Health (1978) 7.80
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet (2009) 6.91
The National Lung Screening Trial: overview and study design. Radiology (2010) 6.43
The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials (2000) 6.17
Lung cancer susceptibility locus at 5p15.33. Nat Genet (2008) 5.99
On criteria for evaluating models of absolute risk. Biostatistics (2005) 5.71
A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet (2009) 5.62
Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet (2008) 5.43
Variations in lung cancer risk among smokers. J Natl Cancer Inst (2003) 5.00
Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis. J Natl Cancer Inst (2006) 4.39
Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 4.29
A risk model for prediction of lung cancer. J Natl Cancer Inst (2007) 4.25
Chronic inflammation and cancer. Oncology (Williston Park) (2002) 3.82
Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol (2007) 3.24
The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer (2007) 3.15
Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. J Natl Cancer Inst (2005) 2.24
An expanded risk prediction model for lung cancer. Cancer Prev Res (Phila) (2008) 2.05
A prospectively measured serum biomarker for a tobacco-specific carcinogen and lung cancer in smokers. Cancer Epidemiol Biomarkers Prev (2009) 2.04
C-reactive protein and risk of lung cancer. J Clin Oncol (2010) 1.90
Body mass and 26-year risk of mortality from specific diseases among women who never smoked. Epidemiology (1998) 1.86
Differential association of body mass index and fat distribution with three major histologic types of lung cancer: evidence from a cohort of older women. Am J Epidemiol (2002) 1.81
Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection. J Clin Oncol (2009) 1.68
Development and validation of a lung cancer risk prediction model for African-Americans. Cancer Prev Res (Phila) (2008) 1.63
Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer. Curr Opin Pulm Med (2009) 1.60
Validation of a model of lung cancer risk prediction among smokers. J Natl Cancer Inst (2006) 1.55
Body mass index and waist circumference in relation to lung cancer risk in the Women's Health Initiative. Am J Epidemiol (2008) 1.48
Smoking and lung cancer: the role of inflammation. Proc Am Thorac Soc (2008) 1.31
Body mass index as a predictor of cancer in men. J Natl Cancer Inst (1985) 1.31
Body Mass Index at the age of 18 and its effects on 32-year-mortality from coronary heart disease and cancer. A nested case-control study among the entire 1932 Dutch male birth cohort. J Clin Epidemiol (1989) 1.25
Sputum cytological atypia as a predictor of incident lung cancer in a cohort of heavy smokers with airflow obstruction. Cancer Epidemiol Biomarkers Prev (2003) 1.22
Leanness and lung-cancer risk. Int J Cancer (1991) 1.21
Body mass index modulates aromatic DNA adduct levels and their persistence in smokers. Cancer Epidemiol Biomarkers Prev (2002) 1.16
Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway. Neoplasia (2007) 1.12
Chronic inflammation as inductor of pro-cancer microenvironment: pathogenesis of dysregulated feedback control. Cancer Metastasis Rev (2003) 1.12
Incremental value of pulmonary function and sputum DNA image cytometry in lung cancer risk prediction. Cancer Prev Res (Phila) (2011) 1.10
Body mass index and lung cancer risk in women. Epidemiology (2007) 1.08
Chronic inflammation, immunosuppression and cancer: new insights and outlook. Semin Cancer Biol (2006) 1.08
Chlamydia pneumoniae infection and risk for lung cancer. Cancer Epidemiol Biomarkers Prev (2010) 1.07
Body mass index and oxidative DNA damage: a longitudinal study. Cancer Sci (2007) 1.07
Prediction of true positive lung cancers in individuals with abnormal suspicious chest radiographs: a prostate, lung, colorectal, and ovarian cancer screening trial study. J Thorac Oncol (2009) 1.03
Lung carcinoma in African Americans and whites. A population-based study in metropolitan Detroit, Michigan. Cancer (1997) 1.03
Evaluating health risk models. Stat Med (2010) 1.00
Are lean smokers at increased risk of lung cancer? The Israel Civil Servant Cancer Study. Arch Intern Med (1996) 0.95
Leanness, smoking, and enhanced oxidative DNA damage. Cancer Epidemiol Biomarkers Prev (2006) 0.94
Is obesity a preventive factor for lung cancer? Neoplasma (2008) 0.93
Defining high-risk individuals in a population-based molecular-epidemiological study of lung cancer. Int J Oncol (2006) 0.91
Lung cancer screening: improved survival but no reduction in deaths--the role of "overdiagnosis". Cancer (2000) 0.89
Lung cancer mortality and body mass index in a Japanese cohort: findings from the Japan Collaborative Cohort Study (JACC Study). Cancer Causes Control (2007) 0.81
Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med (2011) 38.61
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet (2007) 22.96
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med (2003) 9.18
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39
Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA (2007) 7.93
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45
The National Lung Screening Trial: overview and study design. Radiology (2010) 6.43
Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med (2013) 5.92
Long-term mortality after screening for colorectal cancer. N Engl J Med (2013) 5.81
Performance of common genetic variants in breast-cancer risk models. N Engl J Med (2010) 5.79
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood (2009) 5.69
A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet (2009) 5.62
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol (2010) 4.84
Quality control and quality assurance in genotypic data for genome-wide association studies. Genet Epidemiol (2010) 4.83
Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med (2014) 4.76
Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood (2003) 4.67
Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med (2013) 4.64
Colorectal cancer in patients under close colonoscopic surveillance. Gastroenterology (2005) 4.31
B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med (2009) 4.27
Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. PLoS Genet (2010) 3.91
Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One (2008) 3.87
Results of repeat sigmoidoscopy 3 years after a negative examination. JAMA (2003) 3.82
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Selection criteria for lung-cancer screening. N Engl J Med (2013) 3.69
Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest (2006) 3.59
Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol (2009) 3.59
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int (2008) 3.51
Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. J Natl Cancer Inst (2003) 3.44
Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res (2008) 3.39
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Methods for etiologic and early marker investigations in the PLCO trial. Mutat Res (2005) 3.33
Utilization of surveillance colonoscopy in community practice. Gastroenterology (2009) 3.33
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) (2011) 3.33
Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood (2005) 3.25
Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol (2005) 3.25
American Cancer Society lung cancer screening guidelines. CA Cancer J Clin (2013) 3.16
Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities. J Natl Cancer Inst (2010) 3.16
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) (2011) 3.03
Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol (2005) 3.01
Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet (2010) 2.96
Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc (2007) 2.91
A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas. N Engl J Med (2015) 2.88
Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst (2005) 2.82
Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer (2005) 2.79
Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med (2013) 2.77
Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med (2013) 2.66
Long-term disease-specific functioning among prostate cancer survivors and noncancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial. J Clin Oncol (2012) 2.62